| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1374539 | Bioorganic & Medicinal Chemistry Letters | 2010 | 4 Pages |
Abstract
The lead optimization of a series of N-substituted benzimidazole CXCR4 antagonists is described. Side chain modifications and stereochemical optimization led to substantial improvements in potency and protein shift to afford compounds with low nanomolar anti-HIV activity.
Graphical abstractThe lead optimization of a series of N-substituted benzimidazole CXCR4 antagonists is described. Side chain modifications and stereochemical optimization led to substantial improvements in potency and protein shift to afford compounds with low nanomolar anti-HIV activity.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
John F. Miller, Elizabeth M. Turner, Kristjan S. Gudmundsson, Stephen Jenkinson, Andrew Spaltenstein, Michael Thomson, Pat Wheelan,